Associated Papers
Multi-gene panel sequencing reveals the relationship between driver gene mutation and clinical characteristics in lung adenocarcinoma.
Li J et al.
Discover Oncology, 2025
40053265 (PubMed )
Supplement: 12672_2025_2008_MOESM1_ESM.xlsx › Table_S2
Utility of Circulating Tumor DNA Assay in Identifying Mutations and Guiding Matched Targeted Therapy in Lung Cancers.
Li K et al.
Clinical Medicine Insights. Oncology, 2024
39429681 (PubMed )
Supplement: sj-xlsx-9-onc-10.1177_11795549241285238.xlsx › Sheet1
Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects.
Ishiyama N et al.
Cancer Research, 2023
35503682 (PubMed )
Supplement: can-21-0940_supplementary_data_suppsd.docx
Whole-exome sequencing reveals a comprehensive germline mutation landscape and identifies twelve novel predisposition genes in Chinese prostate cancer patients.
Liang Y et al.
Plos Genetics, 2022
36095024 (PubMed )
Supplement: pgen.1010373.s022.xlsx › S7_Table
Clinicopathologic Characteristics of Grade 2/3 Meningiomas: A Perspective on the Role of Next-Generation Sequencing.
Kim J et al.
Frontiers in Oncology, 2022
35774130 (PubMed )
Supplement: DataSheet_2.xlsx › Sheet2
Mutational Profile and Potential Molecular Therapeutic Targets of Pheochromocytoma.
Ma X et al.
Frontiers in Endocrinology, 2022
Identifying Actionable Variants Using Capture-Based Targeted Sequencing in 563 Patients With Non-Small Cell Lung Carcinoma.
Jiang H et al.
Frontiers in Oncology, 2021
35186718 (PubMed )
Supplement: Table_1.xlsx › Supplementary_Table_2
Clinicopathological and Molecular Analysis of 45 Cases of Pure Mucinous Breast Cancer.
Yim HE et al.
Frontiers in Oncology, 2020
HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2-negative patients.
Si P et al.
Cancer Medicine, 2017
HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.
Wang T et al.
Cancer Science, 2017
Select a paper to view details